

Synthesis of 1,5-dihydro-3-methyl-6-trihalomethyl-4*H*-pyrazolo[3,4-*d*]pyrimidin-4-ones

Mikhail V. Vovk,* Andrei V. Bol'but, Vyacheslav I. Boiko, Vladimir V. Pirozhenko and Aleksandr N. Chernega

Institute of Organic Chemistry, National Academy of Sciences of Ukraine, 02094 Kiev, Ukraine.

Fax: +380 44 543 6843; e-mail: hefpos@ukrpack.net

10.1070/MC2001v011n05ABEH001479

N-(Methoxycarbonyl)trihaloacetimidoylchlorides react with 5-aminopyrazoles under mild conditions to give *N*-methoxycarbonyl-*N'*-(5-pyrazolyl)trihaloacetamidines, which furnish 6-trihalomethyl-4*H*-pyrazolo[3,4-*d*]pyrimidin-4-ones by thermal intramolecular cyclocondensation.


Pyrazolo[3,4-*d*]pyrimidines represent a general class of adenosine receptor antagonists.^{1,2} Their effect on adenosine receptor selectivity is determined by the nature of substituents at the atoms N(1), C(4) and C(6).^{3–5} The starting substances for the preparation of 4-substituted 1*H*-pyrazolo[3,4-*d*]pyrimidines⁶ are 4*H*-pyrazolo[3,4-*d*]pyrimidin-4-ones, which are obtained by the condensation of 5-amino-1*H*-pyrazole-4-carboxamides with formamide⁶ or esters.⁷ In particular, 4*H*-pyrazolo[3,4-*d*]pyrimidin-4-ones containing alkyl, phenyl and alkoxy carbonyl substituents at the 6-position can be synthesised. Here we report a new synthetic approach to 6-trihalomethyl-4*H*-pyrazolo[3,4-*d*]pyrimidin-4-ones. The introduction of trifluoromethyl groups into the above molecules is expected to enhance their lipophilicity.^{8,9} In turn, a trichloromethyl group facilitates the introduction of amino groups at the 6-position by *ipso* substitution.¹⁰

The method proposed is based on the use of *N*-(methoxycarbonyl)trihaloacetimidoylchlorides **1a,b**¹¹ as new synthetic units, which react with 2-aminopyrazoles **2a–d** to form a pyrimidine ring.

We found that compounds **1a,b** react with 1-alkyl(aryl, hetaryl)-5-aminopyrazoles **2a–d** in benzene at room temperature in the presence of triethylamine to give *N*-methoxycarbonyl-*N'*-(5-pyrazolyl)trihaloacetamidines **3a–g** in high yields. The structures of these compounds corroborated by elemental analysis and spectroscopy.[†] ¹H NMR signals from 4-H protons of the pyrazole ring observed at 5.90–6.09 ppm for compounds **3a–f** (and at 6.68 ppm for compound **3g**) unambiguously confirm the *N*-acylation of amines **2a–d** by imidoylchlorides **1a,b**.

On boiling *N*-(methoxycarbonyl)amidines **3a–e,g** in toluene and amidine **3f** in *o*-xylene for 3 h, they were converted into 3-methyl-6-trihalomethyl-4*H*-pyrazolo[3,4-*d*]pyrimidin-4-ones **4a–g** in satisfactory or high yields.[‡]

The cyclization most likely occurs through the electrophilic attack of the carbonyl group at the π -electron-rich C-4 atom of the pyrazole ring. However, the thermolysis of *N*-(methoxycarbonyl)amidine to isocyanate,^{12,13} a more electrophilic system, which in fact attacks the pyrazole nucleus, can also take place.



Scheme 1

The structure of compounds **4a–g** was supported by elemental analysis and IR, ¹H, ¹⁹F and ¹³C NMR spectroscopic data and X-ray diffraction analysis, which was carried out for **4g** (Figure 1). The N(1–4)C(1–5) bicyclic system is planar: the atom devia-

[†] Melting points were determined using a Thomas–Hoover apparatus. The IR spectra were measured in KBr pellets. The ¹H, ¹³C and ¹⁹F NMR spectra were measured at 300.0, 75.5, and 282.24 MHz, respectively, in [²H₆]DMSO with SiMe₄ (¹H and ¹³C) and CFCl₃ (¹⁹F) internal standards.

The general procedure for the preparation of *N*-methoxycarbonyl-*N'*-(5-pyrazolyl)trihaloacetamidines **3a–g**. A solution or suspension of amino-pyrazole **2a–d** (5 mmol) and triethylamine (5 mmol, 0.69 ml) in benzene (10 ml) was added to a solution of imidoylchloride **1a,b** (5 mmol) in benzene (10 ml) with stirring at room temperature. After additional stirring for 2 h, the mixture was heated to boiling, and the resulting triethylamine hydrochloride precipitate was filtered off. The filtrate was evaporated, and the residue was crystallised from benzene.

N'-[1-(2-Cyanoethyl)-3-methyl-1*H*-pyrazol-5-yl]-*N*-methoxycarbonyl-trifluoroacetamide **3a**: yield 85%, mp 91–92 °C. ¹H NMR, δ : 2.28 (s, 3H, Me), 2.88 (t, 2H, CH₂, *J* 6.9 Hz), 3.79 (s, 3H, OMe), 4.59 (t, 2H, CH₂N, *J* 6.9 Hz), 5.91 (s, 1H, 4-*H*_{pyrazole}), 7.32 (s, 1H, NH). ¹⁹F NMR, δ : -71.5 (s, CF₃). IR (ν /cm⁻¹): 3090 (NH), 2260 (CN), 1735 (C=O). Found (%): C, 43.64; H, 4.14; N, 22.78; F, 18.64. Calc. for C₁₁H₁₂F₃N₅O₂ (%): C, 43.57; H, 3.99; N, 23.09; F, 18.80.

N'-[1-(2-Cyanoethyl)-3-methyl-1*H*-pyrazol-5-yl]-*N*-methoxycarbonyl-trichloroacetamide **3b**: yield 87%, mp 138–139 °C. ¹H NMR, δ : 2.27 (s, 3H, Me), 2.91 (t, 2H, CH₂, *J* 7.2 Hz), 3.74 (s, 3H, OMe), 4.52 (t, 2H, CH₂N, *J* 7.2 Hz), 5.90 (s, 1H, 4-*H*_{pyrazole}), 7.34 (s, 1H, NH). IR (ν /cm⁻¹): 3075 (NH), 2260 (CN), 1730 (C=O). Found (%): C, 37.70; H, 3.44; N, 19.75; Cl, 30.35. Calc. for C₁₁H₁₂Cl₃N₅O₂ (%): C, 37.47; H, 3.43; N, 19.86; Cl, 30.16.

N-Methoxycarbonyl-*N'*-(3-methyl-1-phenyl-1*H*-pyrazol-5-yl)trifluoroacetamide **3c**: yield 96%, mp 111–112 °C. ¹H NMR, δ : 2.35 (s, 3H, Me), 3.75 (s, 3H, OMe), 6.01 (s, 1H, 4-*H*_{pyrazole}), 7.31 (t, 1H, 4'-*H*, *J* 6.6 Hz), 7.42 (m, 2H, 3'-*H*, 5'-*H*), 7.51 (s, 1H, NH), 7.59 (d, 2H, 2'-*H*, 6'-*H*, *J* 7.6 Hz). ¹⁹F NMR, δ : -71.9 (s, CF₃). IR (ν /cm⁻¹): 3100 (NH), 1740 (C=O). Found (%): C, 51.79; H, 3.83; N, 17.41; F, 17.56. Calc. for C₁₄H₁₃F₃N₄O₂ (%): C, 51.54; H, 4.02; N, 17.17; F, 17.47.

N-Methoxycarbonyl-*N'*-(3-methyl-1-phenyl-1*H*-pyrazol-5-yl)trichloroacetamide **3d**: yield 95%, mp 112–113 °C. ¹H NMR, δ : 2.25 (s, 3H, Me), 3.83 (s, 3H, OMe), 5.93 (s, 1H, 4-*H*_{pyrazole}), 6.95 (t, 1H, 4'-*H*, *J* 6.8 Hz), 7.12 (m, 2H, 3'-*H*, 5'-*H*), 7.56 (s, 1H, NH), 7.90 (d, 2H, 2'-*H*, 6'-*H*, *J* 7.9 Hz). IR (ν /cm⁻¹): 3080 (NH), 1745 (C=O). Found (%): C, 44.38; H, 3.65; N, 15.07; Cl, 21.59. Calc. for C₁₄H₁₃Cl₃N₄O₂ (%): C, 44.76; H, 3.49; N, 14.92; Cl, 28.31.

N'-[1-[2-Chloro-5-(trifluoromethyl)phenyl]-3-methyl-1*H*-pyrazol-5-yl]-*N*-methoxycarbonyltrifluoroacetamide **3e**: yield 68%, mp 127–128 °C. ¹H NMR, δ : 2.38 (s, 3H, Me), 3.82 (s, 3H, OMe), 6.06 (s, 1H, 4-*H*_{pyrazole}), 7.29 (s, 1H, NH), 7.64 (s, 2H, 3'-*H*, 4'-*H*), 7.74 (s, 1H, 6'-*H*). ¹⁹F NMR, δ : -63.9 (s, CF₃), -71.6 (s, CF₃). IR (ν /cm⁻¹): 3100 (NH), 1740 (C=O). Found (%): C, 42.11; H, 2.69; N, 13.32; F, 26.38. Calc. for C₁₅H₁₁ClF₆N₄O₂ (%): C, 42.02; H, 2.59; N, 13.07; F, 26.59.

N'-[1-[2-Chloro-5-(trifluoromethyl)phenyl]-3-methyl-1*H*-pyrazol-5-yl]-*N*-methoxycarbonyltrichloroacetamide **3f**: yield 77%, mp 160–161 °C. ¹H NMR, δ : 2.38 (s, 3H, Me), 3.77 (s, 3H, OMe), 6.09 (s, 1H, 4-*H*_{pyrazole}), 7.26 (s, 1H, NH), 7.62 (s, 2H, 3'-*H*, 4'-*H*), 7.76 (s, 1H, 6'-*H*). IR (ν /cm⁻¹): 3100 (NH), 1735 (C=O). Found (%): C, 37.71; H, 2.45; N, 11.47; Cl, 29.43. Calc. for C₁₅H₁₁Cl₄F₃N₄O₂ (%): C, 37.68; H, 2.32; N, 11.72; Cl, 29.66.

N-Methoxycarbonyl-*N'*-[3-methyl-1-(2-pyridinyl)-1*H*-pyrazol-5-yl]trichloroacetamide **3g**: yield 73%, mp 139–140 °C. ¹H NMR, δ : 2.32 (s, 3H, Me), 3.83 (s, 3H, OMe), 6.68 (s, 1H, 4-*H*_{pyrazole}), 7.16 (m, 1H, *H*_{pyridine}), 7.86–8.04 (m, 3H, *H*_{pyridine}), 13.6 (s, 1H, NH). IR (ν /cm⁻¹): 3100 (NH), 1725 (C=O). Found (%): C, 41.69; H, 3.07; N, 18.84; Cl, 28.60. Calc. for C₁₃H₁₂Cl₃N₅O₂ (%): C, 41.46; H, 3.21; N, 18.59; Cl, 28.24.

tions from the least-squares plane do not exceed 0.04 Å, the dihedral angle between N(1)N(2)C(1–3) and N(3)N(4)C(3–5) cycles being only 2.9°. The N(5)C(8–12) ring is turned out from

‡ The general procedure for the preparation of 3-methyl-6-trihalomethyl-4H-pyrazolo[3,4-d]pyrimidin-4-ones **4a–g**. Toluene (10 ml) or *o*-xylene (10 ml, for compound **3g**) was added to compound **3a–f** (3 mmol), and the reaction mixture was refluxed for 3 h. The product precipitated on cooling was filtered off and crystallised from acetonitrile (for compounds **4a, 4b, 4e, 4f**) or from an ethanol–DMF mixture (for compounds **4c, 4d, 4g**).

1-(2-Cyanoethyl)-3-methyl-6-trifluoromethyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one **4a**: yield 68%, mp 202–203 °C. ¹H NMR, δ: 2.50 (s, 3H, Me), 3.12 (t, 2H, CH₂, *J* 6.9 Hz), 4.52 (t, 2H, CH₂N, *J* 6.9 Hz), 13.70 (s, 1H, NH). ¹³C NMR, δ: 13.11 (Me), 17.73 (CH₂), 42.38 (CH₂N), 104.03 [C(3a)], 117.84 (q, CF₃, ¹*J*_{C–F} 276.5 Hz), 118.14 (CN), 145.39 [C(3)], 145.84 [C(6)], ²*J*_{C–F} 37.4 Hz), 150.98 [C(7a)], 158.39 (C=O). ¹⁹F NMR, δ: –68.9 (s, CF₃). IR (ν/cm^{–1}): 3170, 3080 (NH), 1690 (C=O). Found (%): C, 44.07; H, 3.17; N, 25.90; F, 21.23. Calc. for C₁₀H₈F₃N₅O (%): C, 44.29; H, 2.97; N, 25.82; F, 21.02.

1-(2-Cyanoethyl)-3-methyl-6-trichloromethyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one **4b**: yield 62%, mp 183–184 °C. ¹H NMR, δ: 2.49 (s, 3H, Me), 3.16 (t, 2H, CH₂, *J* 7.1 Hz), 4.52 (t, 2H, CH₂N, *J* 7.1 Hz), 13.36 (s, 1H, NH). ¹³C NMR, δ: 13.12 (Me), 17.55 (CH₂), 42.37 (CH₂N), 92.01 (CCl₃), 102.51 [C(3a)], 118.15 (CN), 145.19 [C(3)], 150.62 [C(7a)], 154.09 [C(6)], 158.60 (C=O). IR (ν/cm^{–1}): 3160, 3060 (NH), 1695 (C=O). Found (%): C, 37.20; H, 2.54; N, 22.09; Cl, 33.03. Calc. for C₁₀H₈Cl₃N₅O (%): C, 37.47; H, 2.52; N, 21.85; Cl, 33.18.

3-Methyl-1-phenyl-6-trifluoromethyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one **4c**: yield 85%, mp 266–267 °C. ¹H NMR, δ: 2.57 (s, 3H, Me), 7.41 (t, 1H, 4'-H, *J* 6.9 Hz), 7.58 (m, 2H, 3'-H, 5'-H), 7.97 (d, 2H, 2'-H, 6'-H, *J* 7.8 Hz), 13.98 (s, 1H, NH). ¹³C NMR, δ: 13.06 (Me), 105.71 [C(3a)], 117.74 (q, CF₃, ¹*J*_{C–F} 273.4 Hz), 121.31 [C(2'), C(6')], 126.89 [C(4')], 129.01 [C(3')], 137.68 [C(1')], 145.87 [C(3)], 146.28 [C(6)], ²*J*_{C–F} 37.3 Hz), 150.43 [C(7a)], 158.70 (C=O). ¹⁹F NMR, δ: –69.0 (s, CF₃). IR (ν/cm^{–1}): 3180, 3080 (NH), 1700 (C=O). Found (%): C, 53.16; H, 3.36; N, 18.79; F, 19.55. Calc. for C₁₃H₉F₃N₄O (%): C, 53.07; H, 3.08; N, 19.04; F, 19.37.

3-Methyl-1-phenyl-6-trichloromethyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one **4d**: yield 82%, mp 252–253 °C. ¹H NMR, δ: 2.58 (s, 3H, Me), 7.40 (t, 1H, 4'-H, *J* 6.9 Hz), 7.57 (m, 2H, 3'-H, 5'-H), 8.09 (d, 2H, 2'-H, 6'-H, *J* 7.8 Hz), 14.02 (s, 1H, NH). ¹³C NMR, δ: 13.22 (Me), 92.35 (CCl₃), 104.30 [C(3a)], 120.83 [C(2'), C(6')], 126.76 [C(4')], 129.16 [C(3')], 137.88 [C(1')], 149.9 [C(7a)], 154.70 [C(6)], 159.20 (C=O). IR (ν/cm^{–1}): 3180, 3060 (NH), 1700 (C=O). Found (%): C, 45.36; H, 2.85; N, 16.30; Cl, 31.26. Calc. for C₁₃H₉Cl₃N₄O (%): C, 45.44; H, 2.64; N, 16.31; Cl, 30.95.

1-[2-Chloro-5-(trifluoromethyl)phenyl]-3-methyl-6-trifluoromethyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one **4e**: yield 89%, mp 258–259 °C. ¹H NMR, δ: 2.59 (s, 3H, Me), 8.04 (s, 2H, 3'-H, 4'-H), 8.14 (s, 1H, 6'-H), 13.73 (s, 1H, NH). ¹³C NMR, δ: 13.13 (Me), 104.86 [C(3a)], 117.72 (q, CF₃, ¹*J*_{C–F} 276.4 Hz), 123.03 (q, CF₃ in the aromatic ring, ¹*J*_{C–F} 272.5 Hz), 126.97 [q, C(4')], ³*J*_{C–F} 4.5 Hz), 127.99 [q, C(6')], ³*J*_{C–F} 3.2 Hz), 128.79 [q, C(5')], ²*J*_{C–F} 33.4 Hz), 131.68 [C(3')], 134.94 [C(1')], 135.24 [C(2')], 146.83 [C(6)], ²*J*_{C–F} 36.9 Hz), 146.85 [C(3)], 152.47 [C(7a)], 158.71 (C=O). ¹⁹F NMR, δ: –61.5 (s, CF₃, in the aromatic ring), –69.0 (s, CF₃). IR (ν/cm^{–1}): 3190, 3080 (NH), 1720 (C=O). Found (%): C, 42.13; H, 1.89; N, 14.43; F, 28.97. Calc. for C₁₄H₇ClF₆N₄O (%): C, 42.39; H, 1.78; N, 14.12; F, 28.74.

1-[2-Chloro-5-(trifluoromethyl)phenyl]-3-methyl-6-trichloromethyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one **4f**: yield 40%, mp 207–208 °C. ¹H NMR, δ: 2.58 (s, 3H, Me), 8.01 (s, 2H, 3'-H, 4'-H), 8.16 (s, 1H, 6'-H), 13.60 (s, 1H, NH). ¹³C NMR, δ: 13.17 (Me), 92.02 (CCl₃), 103.40 [C(3a)], 123.08 (q, CF₃ in the aromatic ring, ¹*J*_{C–F} 272.7 Hz), 126.96 [q, C(4')], ³*J*_{C–F} 3.8 Hz), 127.72 [q, C(6')], ³*J*_{C–F} 3.2 Hz), 128.71 [q, C(5')], ²*J*_{C–F} 33.0 Hz), 131.67 [C(3')], 134.95 [C(1')], 135.02 [C(2')], 146.78 [C(3)], 152.11 [C(7a)], 155.21 [C(6)], 158.95 (C=O). IR (ν/cm^{–1}): 3170, 3050 (NH), 1685 (C=O). Found (%): C, 37.51; H, 1.38; N, 12.71; Cl, 31.52. Calc. for C₁₄H₇Cl₄F₃N₄O (%): C, 37.70; H, 1.58; N, 12.56; Cl, 31.79.

3-Methyl-1-(2-pyridinyl)-6-trichloromethyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one **4g**: yield 64%, mp 241–242 °C. ¹H NMR, δ: 2.58 (s, 3H, Me), 7.49 (m, 1H, H_{pyridine}), 8.06 (m, 2H, H_{pyridine}), 8.03 (s, 1H, NH), 8.60 (m, 1H, H_{pyridine}). ¹³C NMR, δ: 13.22 (Me), 92.43 (CCl₃), 104.38 [C(3a)], 117.27 [C(3')], 123.04 [C(5')], 138.78 [C(4')], 146.21 [C(3)], 148.74 [C(6')], 149.54 [C(2')], 150.82 [C(7a)], 155.01 [C(6)], 159.11 (C=O). IR (ν/cm^{–1}): 3160, 3070 (NH), 1670 (C=O). Found (%): C, 41.95; H, 2.38; N, 20.03; Cl, 31.09. Calc. for C₁₂H₈Cl₃N₅O (%): C, 41.83; H, 2.34; N, 20.32; Cl, 30.87.




Figure 1 Molecular structure of **4g**. Selected bond lengths (Å): N(1)–C(1) 1.355(3), N(1)–C(2) 1.401(3), N(2)–C(1) 1.290(3), N(2)–C(4) 1.361(3), N(3)–N(4) 1.386(3), N(3)–C(5) 1.317(3), N(4)–C(4) 1.361(3), C(2)–C(3) 1.423(3), C(3)–C(4) 1.417(3), C(3)–C(5) 1.417(3).

the bicyclic plane by 23.0°. In a crystal, molecules of **4g** are joined in dimeric pairs by the intermolecular hydrogen bonds N(1)–H(1)⋯O(1) [O(1)⋯N(1) 2.803(3), O(1)⋯H(1) 1.93(4), N(1)–H(1) 0.88(4) Å, O(1)H(1)N(1) 171(2)°].[§]

References

- L. P. Davies, D. J. Brown, S. C. Chow and G. A. Johnston, *Neurosci. Lett.*, 1983, **41**, 189.
- L. P. Davies, S. C. Chow, J. H. Skerritt, D. J. Brown and G. A. Johnston, *Life Sci.*, 1984, **34**, 2117.
- R. J. Quinn, P. J. Scammells and D. J. Tucker, *Aust. J. Chem.*, 1991, **44**, 753.
- F. A. Harden, R. J. Quinn and P. J. Scammells, *J. Med. Chem.*, 1991, **34**, 2892.
- M. Chebib and R. J. Quinn, *J. Bioorg. Med. Chem. Lett.*, 1995, **5**, 2409.
- C. C. Cheng and R. K. Robins, *J. Org. Chem.*, 1956, **21**, 1240.
- A. Miyashita, C. Lijima and T. Higashino, *Heterocycles*, 1990, **31**, 1309.
- H. A. McClintock and D. A. McClintock, *Tetrahedron*, 1992, **48**, 6555.
- A. S. Kiselyov and L. Strekowski, *Org. Prep. Proced. Int.*, 1996, **28**, 289.
- D. N. Kozhevnikov, V. N. Kozhevnikov, V. L. Rusinov and O. N. Chupakhin, *Khim. Geterotsikl. Soedin.*, 1999, 1574 [*Chem. Heterocycl. Compd. (Engl. Transl.)*, 1999, **35**, 1377].
- L. I. Samarai, V. I. Boyko and M. N. Gertsyuk, *Zh. Org. Khim.*, 1990, **26**, 745 [*J. Org. Chem. USSR (Engl. Transl.)*, 1990, **26**, 640].
- K. Uneyama, F. Yamashita, K. Sugimoto and O. Morimoto, *Tetrahedron Lett.*, 1990, **31**, 2717.
- V. I. Boiko, M. V. Vovk and L. I. Samarai, *Ukr. Khim. Zh.*, 1995, **61**, 48 (in Ukrainian).
- C. T. North, D. C. Phillips and F. S. Mathews, *Acta Crystallogr.*, 1968, **A24**, 351.
- D. J. Watkin, C. K. Prout, J. R. Carruthers and P. W. Betteridge, *Crystals Issue 10*. Oxford: Chemical Crystallography Laboratory, University of Oxford, 1996.
- J. R. Carruthers and D. J. Watkin, *Acta Crystallogr.*, 1979, **A35**, 698.

Received: 23rd May 2001; Com. 01/1805

[§] Crystal data for **4g**: C₁₂H₈Cl₃N₅O, *M* = 344.59, monoclinic, space group *P2₁/c* (no. 14), *a* = 10.738(1) Å, *b* = 12.553(1) Å, *c* = 10.818(1) Å, β = 93.06(1)°, *V* = 1456.1(4) Å³, *Z* = 4, *d*_{calc} = 1.572 g cm^{–3}, μ = 58.86 cm^{–1}, *F*(000) = 702, crystal size of 0.53×0.53×0.56 mm. All data were collected using CuKα radiation (λ = 1.54178 Å) on an Enraf-Nonius CAD4 diffractometer, θ_{max} = 70°, 293 K, 3056 reflections collected (2755 independent, *R*_{int} = 0.034). An empirical absorption correction based on azimuthal scan data¹⁴ was applied. The structure was solved by direct methods and refined by a full-matrix least-squares technique in the anisotropic approximation using the CRYSTALS¹⁵ program package. All hydrogen atoms were located in the different Fourier maps and included in the final refinement with fixed positional and thermal parameters [only the H(1) atom was refined isotropically]. Convergence was obtained at *R* = 0.046 and *R*_w = 0.050, GOF = 1.121 [2147 reflections with *I* > 3σ(*I*), 194 refined parameters; obs/variabl. 11.1, difference electron density 0.40 and –0.46 e Å^{–3}, Chebyshev weighting scheme¹⁶ with parameters of 12.5, –8.04, 15.0, –3.3 and 4.4]. Atomic coordinates, bond lengths, bond angles and thermal parameters have been deposited at the Cambridge Crystallographic Data Centre (CCDC). For details, see ‘Notice to Authors’, *Mendelevy Commun.*, Issue 1, 2001. Any request to the CCDC for data should quote the full literature citation and the reference number 1135/95.